Evidence map›Paper›PMID 38914806›Full record

ArticleJournal of cancer research and clinical oncology2024

Circular RNA circLIFR suppresses papillary thyroid cancer progression by modulating the miR-429/TIMP2 axis.

Fengyuan Zhang, Jiazheng Li, Jingjing Xu, Xugan Jiang, Shengxia Chen, Qais Ahmad Nasser

Abstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fengyuan ZhangDepartment of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, 212013, China.
Jiazheng LiDepartment of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, 212013, China.
Jingjing XuDepartment of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, 212013, China.
Xugan JiangDepartment of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, 212013, China.
Shengxia ChenDepartment of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, 212013, China. chensxia@ujs.edu.cn.
Qais Ahmad NasserDepartment of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, 212013, China. kaise.khan47@hotmail.com.

Funding

the Basic Platform Project of the Ministry of Science and Technology of China TDRC-2019-194-30
6 · The paper itself

Abstract

purposeCircular RNAs (circRNAs) are increasingly recognized for their important roles in various cancers, including papillary thyroid cancer (PTC). The specific mechanisms by which the circLIF receptor subunit alpha (circLIFR, hsa_circ_0072309) influences PTC progression remain largely unknown.

methodsIn our study, CircLIFR, miR-429, and TIMP2 levels were assessed using reverse transcription-quantitative PCR. The roles of circLIFR and miR-429 in PTC cells were determined using Cell Counting Kit-8, colony formation, wound healing, and Transwell assays. Western blotting was utilized to examine the levels of TIMP2. The direct interaction between circLIFR, TIMP2, and miR-429 was confirmed using dual-luciferase reporter, RNA immunoprecipitation, and fluorescence in situ hybridization assays.

resultsIn PTC tissues and cells, a decrease in circLIFR and TIMP2 levels, accompanied by an increase in miR-429 levels, was observed. Overexpression of circLIFR or downregulation of miR-429 effectively suppressed the proliferation and migration of PTC cells. Conversely, the knockdown of circLIFR or overexpression of miR-429 had the opposite effect. Furthermore, circLIFR overexpression suppressed tumor growth in vivo. Mechanistically, circLIFR modulated TIMP2 expression by serving as a sponge for miR-429. Rescue experiments indicated that the antitumor effect of circLIFR could be reversed by miR-429.

conclusionThis study confirmed circLIFR as a novel tumor suppressor delayed PTC progression through the miR-429/TIMP2 axis. These findings suggested that circLIFR held promise as a potential therapeutic target for PTC.

Indexed as

Cell ProliferationDisease ProgressionMicroRNAsRNA, CircularThyroid Cancer, PapillaryThyroid NeoplasmsTissue Inhibitor of Metalloproteinase-2AnimalsCell Line, TumorCell MovementFemaleGene Expression Regulation, NeoplasticHumansLeukemia Inhibitory Factor Receptor alpha SubunitMaleMiceLeukemia Inhibitory Factor Receptor alpha SubunitLIFR protein, humanMicroRNAsMIRN429 microRNA, humanRNA, CircularTIMP2 protein, humanTissue Inhibitor of Metalloproteinase-2CircLIFRCircular RNAmiR-429Papillary thyroid cancerTIMP2

Identifiers

PMID38914806
PMCPMC11196293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.